NSE · SAILIFE · Pharmaceuticals
Sai Life Sciences Limited
Revenue & net profit by period
Bars = revenue (₹ Cr) · line = net profit (₹ Cr). Straight from disclosed results.
Latest period: revenue ₹547 Cr with net profit ₹71 Cr — a 13.05% net margin, versus 15.57% the period before.
Shareholding
As of 2026-06-30
- Promoter34.53%
- Public13.11%
- FII19.65%
- DII32.71%
1,25,096 shareholders on record
Promoter holding trend
Each disclosed period, oldest to newest
52-week position
Where the current price sits in its yearly band
The band spans 2.16× from low to high.
Risk flags
Derived from disclosed data
No flags raised by the data.
Peer comparison
Pharmaceuticals - Indian - Bulk Drugs & Formln · ranked #17 of 102 by market cap · medians across 49 industry peers
| Company | Mkt cap | P/E | P/B | ROE | Margin |
|---|---|---|---|---|---|
| Sun Pharmaceutical Industries Ltd. | ₹4,46,516 Cr | 35.34 | 5.35 | 13.74% | 20.29% |
| Zydus Lifesciences Ltd. | ₹1,11,501 Cr | 22.84 | 4.11 | 18.59% | 16.09% |
| Cipla Ltd. | ₹1,10,943 Cr | 31 | 3.24 | 11.27% | 12.06% |
| Laurus Labs Limited | ₹1,05,091 Cr | 96.1 | 19.74 | 16.77% | 15.04% |
| Aurobindo Pharma Ltd. | ₹95,996 Cr | 25.39 | 2.53 | 9.25% | 10.7% |
| Dr Reddys Laboratories Ltd. | ₹95,404 Cr | 29.61 | 2.5 | 11.07% | 9.73% |
| Lupin Limited | ₹95,011 Cr | 15.95 | 4.23 | 23.76% | 18.72% |
| Mankind Pharma Limited | ₹92,456 Cr | 43.34 | 5.69 | 11.74% | 13.86% |
| Glenmark Pharmaceuticals Ltd. | ₹68,157 Cr | 21.84 | 6.49 | 28.08% | 10.22% |
| Biocon Ltd. | ₹63,558 Cr | 87.05 | 1.84 | 1.14% | 2.89% |
| Sai Life Sciences Limited(this company) | ₹33,794 Cr | 91.92 | 13.62 | 14.05% | 16.08% |
AI analysis
AI-generated · google/gemini-2.5-flashSai Life Sciences Limited is listed on the Indian markets with a market capitalization of Rs 27535 Cr. The company reported annual revenue of Rs 1731.35 Cr and a profit margin of 15.91%. Its Price-to-Earnings (PE) ratio stands at 77.57, with an Earnings Per Share (EPS) of Rs 16.72. The book value per share is Rs 116.99, and the company has a Debt to Equity ratio of 0.42.
Positives
- +Revenue growth was 15.7% annually for the period ending March 2025.
- +Return on Capital Employed (ROCE) was 18.23% for the period ending March 2025.
- +The debt-to-equity ratio is 0.42, indicating a moderate leverage position.
- +Promoter shareholding is 34.5264% as of June 30, 2026, with no shares pledged.
Negatives
- −The Price-to-Earnings (PE) ratio is 77.57, which is relatively high.
- −Promoter holding decreased from 35.1678% in March 2025 to 34.5264% in June 2026.
- −Public shareholding increased from 13.1111% in June 2026 to 41.0924% in December 2024.
- −Quarterly EPS figures are not provided in the data since March 2025.
Financial Performance
Sai Life Sciences Limited recorded an annual revenue of Rs 1731.35 Cr for the period ending March 2025. This represents a revenue growth of 15.7%. The net profit for the same period was Rs 170.13 Cr. Quarterly revenue for March 2026 was Rs 602.14 Cr, with a net profit of Rs 104.24 Cr.
Profitability & Returns
For the period ending March 2025, Sai Life Sciences Limited reported a profit margin of 15.91%. The company's Return on Equity (ROE) was 14.05%, and Return on Capital Employed (ROCE) was 18.23%. Earnings Per Share (EPS) stood at Rs 16.72 annually.
Balance Sheet
The company's book value per share is Rs 116.99. Sai Life Sciences Limited's debt-to-equity ratio is 0.42, indicating its reliance on debt financing relative to equity. There is no dividend yield reported for the company.
Ownership & Pledges
As of June 30, 2026, promoter holding in Sai Life Sciences Limited was 34.5264%. Domestic Institutional Investors (DII) held 32.713%, while Foreign Institutional Investors (FII) held 19.6495%. The public shareholding was 13.1111%. There were no promoter shares pledged as of the latest reporting period.
Regulatory & Surveillance
The company is not currently listed under any surveillance measures. There is no information provided regarding any pledges on promoter holdings, indicating no shares were pledged at the last reported period.
Data as of — price: 2026-09-11 · financials: Jun 26 · shareholding: Jun 26. Figures are restated only when the company files again, so a period shown here is the most recent one on record — not necessarily the current quarter.
How this is produced: every figure above is computed from exchange filings and financial data mirrored by IPO Plus — no figure is generated or estimated. This is a factual summary for information and education only. It is not investment advice, not a recommendation to buy, sell or hold any security, and contains no price targets. Verify against the company's filings and the exchanges before any decision.